TY - JOUR
T1 - Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response
AU - Yaacobi Peretz, Shiran
AU - Kessner, Rivka
AU - Bar, Yael
AU - Sonnenblick, Amir
AU - Lerner, Shir
AU - Deutsch-Lukatsky, Ariella
AU - Popuri, Karteek
AU - Beg, Mirza Faisal
AU - Shachar, Shlomit Strulov
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Body composition is an important predictor in cancer patients, with skeletal muscle loss and high adiposity associated with poorer prognosis. This study evaluated how body composition affects treatment efficacy in 48 women with metastatic breast cancer receiving trastuzumab deruxtecan. Using computed tomography, skeletal muscle, visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were assessed within 60 days before initiating treatment. High SAT and VAT areas were significantly associated with a higher likelihood of dose reductions (Odds Ratio [OR] = 5.34, p =.032 and OR = 5.52, p = 0.032, respectively). Higher SAT areas correlated with a lower objective response rate (OR = 0.22, p = 0.047). Medium SAT and low/medium VAT densities increased the risk of dose reductions. A body mass index over 25 kg/m2 was linked to higher dose reductions (OR = 4.97, p = 0.016). These findings emphasize the need for personalized treatment strategies based on body composition.
AB - Body composition is an important predictor in cancer patients, with skeletal muscle loss and high adiposity associated with poorer prognosis. This study evaluated how body composition affects treatment efficacy in 48 women with metastatic breast cancer receiving trastuzumab deruxtecan. Using computed tomography, skeletal muscle, visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were assessed within 60 days before initiating treatment. High SAT and VAT areas were significantly associated with a higher likelihood of dose reductions (Odds Ratio [OR] = 5.34, p =.032 and OR = 5.52, p = 0.032, respectively). Higher SAT areas correlated with a lower objective response rate (OR = 0.22, p = 0.047). Medium SAT and low/medium VAT densities increased the risk of dose reductions. A body mass index over 25 kg/m2 was linked to higher dose reductions (OR = 4.97, p = 0.016). These findings emphasize the need for personalized treatment strategies based on body composition.
UR - http://www.scopus.com/inward/record.url?scp=105003760796&partnerID=8YFLogxK
U2 - 10.1038/s41523-025-00754-7
DO - 10.1038/s41523-025-00754-7
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 40281028
AN - SCOPUS:105003760796
SN - 2374-4677
VL - 11
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 38
ER -
